Key Details
Longevity pharmacology has evolved from descriptive gerontology into a mechanistically driven field aiming to modulate fundamental processes of biological aging. Despite rapid scientific advances, whether this progress has translated into meaningful clinical outcomes remains uncertain. This critical perspective evaluates recent developments in longevity pharmacology and examines whether they represent genuine clinical progression or continued translational delay. A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science to identify English-language publications related to longevity pharmacology, gerotherapeutics, biomarkers of aging, and translational geroscience published between January 2000 and April 2026. We review evidence from senescence biology (including frailty), autophagy and mitophagy modulation, metabolic and nutrient-sensing pathways, stem cell and natural product - based rejuvenation strategies, microbiome-targeted interventions, and AI-enabled biomarker development. Particular emphasis is placed on systemic chronic inflammation as a central integrative driver of age-related disease. While selected interventions show early clinical signals, most remain preclinical or lack long-term validation. Key barriers include biomarker deficits, biological heterogeneity, safety concerns, regulatory misalignment, and limitations of animal models. Although mechanistic maturity is advancing rapidly, clinical translation remains incremental and fragmented. Near-term progress is most likely to arise from low-risk, system-level interventions supported by validated biomarkers and geroscience-informed clinical trial designs.
Why This Matters
[Draft — editorial context needed]
